Skip to main content
Genprex, Inc. logo

Genprex, Inc. — Investor Relations & Filings

Ticker · GNPX ISIN · US3724461047 LEI · 549300KS9771JZ234890 US Professional, scientific and technical activities
Filings indexed 465 across all filing types
Latest filing 2025-12-23 Director's Dealing
Country US United States of America
Listing US GNPX

About Genprex, Inc.

https://www.genprex.com/

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapeutic options for large patient populations. Its oncology pipeline includes clinical-stage programs for lung cancer, such as the Acclaim-3 trial in small cell lung cancer (SCLC) and other programs for non-small cell lung cancer (NSCLC). In addition to its cancer programs, Genprex is developing gene therapies for diabetes. The company utilizes a proprietary, non-viral nanoparticle delivery system to systemically deliver therapeutic genes.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2025-12-23 English
FORM 4
Director's Dealing
2025-12-23 English
FORM 8-K
Regulatory Filings
2025-12-23 English
Regulatory Filings 2025
Regulatory Filings
2025-12-15 English
FORM 424B3
Prospectus
2025-12-12 English
FORM S-1/A
Registration Form
2025-11-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.